ArticlePloS one2013
Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Reference miRNAs for colorectal cancer: analysis and verification of current data.Scientific reports · 2017Pooled it
- Exosomal microRNAs as tumor markers in epithelial ovarian cancer.Molecular oncology · 2018Trial
- VEZF1 inhibits ovarian cancer cell ferroptosis and acts as an oncogene via the miR-545-3p/PLAG1 axis.Hereditas · 2026Article
- The downregulation of miR-509-3p expression by collagen type XI alpha 1-regulated hypermethylation facilitates cancer progression and chemoresistance via the DNA methyltransferase 1/Small ubiquitin-like modifier-3 axis in ovarian cancer cells.Journal of ovarian research · 2023Article
- Article
- A two-microRNA signature predicts the progression of male thyroid cancer.Open life sciences · 2021Article
- miR‑802 inhibits the epithelial‑mesenchymal transition, migration and invasion of cervical cancer by regulating BTF3.Molecular medicine reports · 2020Article
- Lasting and Sex-Dependent Impact of Maternal Immune Activation on Molecular Pathways of the Amygdala.Frontiers in neuroscience · 2020Article
- Opioid-Induced Hyperalgesia Is Associated with Dysregulation of Circadian Rhythm and Adaptive Immune Pathways in the Mouse Trigeminal Ganglia and Nucleus Accumbens.Molecular neurobiology · 2019Article
- Survival advantage and clinicopathological significance of microRNA-22 in cancers: a meta-analysis.Cancer management and research · 2019Article
- Disruption of microglia histone acetylation and protein pathways in mice exhibiting inflammation-associated depression-like symptoms.Psychoneuroendocrinology · 2018Article
- Bioinformatics analysis of microarray data to reveal the pathogenesis of diffuse intrinsic pontine glioma.Biological research · 2018Article
- Transcription factor-microRNA associations and their impact on colorectal cancer survival.Molecular carcinogenesis · 2017Article
- Dynamic and Modularized MicroRNA Regulation and Its Implication in Human Cancers.Scientific reports · 2017Article
- Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets.BMC genomics · 2017Article
- Expression of miR-146a in patients with ovarian cancer and its clinical significance.Oncology letters · 2017Article
- MicroRNA-497 inhibits thyroid cancer tumor growth and invasion by suppressing BDNF.Oncotarget · 2017Article
- Article
- Gene Expression Profiling Reveals Novel Candidate Markers of Ovarian Carcinoma Intraperitoneal Metastasis.Journal of Cancer · 2017Article
- Grouping miRNAs of similar functions via weighted information content of gene ontology.BMC bioinformatics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The identification of reliable transcriptome biomarkers requires the simultaneous consideration of regulatory and target elements including microRNAs (miRNAs), transcription factors (TFs), and target genes. A novel approach that integrates multivariate survival analysis, feature selection, and regulatory network visualization was used to identify reliable biomarkers of ovarian cancer survival and recurrence. Expression profiles of 799 miRNAs, 17,814 TFs and target genes and cohort clinical records on 272 patients diagnosed with ovarian cancer were simultaneously considered and results were validated on an independent group of 146 patients. Three miRNAs (hsa-miR-16, hsa-miR-22*, and ebv-miR-BHRF1-2*) were associated with both ovarian cancer survival and recurrence and 27 miRNAs were associated with either one hazard. Two miRNAs (hsa-miR-521 and hsa-miR-497) were cohort-dependent, while 28 were cohort-independent. This study confirmed 19 miRNAs previously associated with ovarian cancer and identified two miRNAs that have previously been associated with other cancer types. In total, the expression of 838 and 734 target genes and 12 and eight TFs were associated (FDR-adjusted P-value <0.05) with ovarian cancer survival and recurrence, respectively. Functional analysis highlighted the association between cellular and nucleotide metabolic processes and ovarian cancer. The more direct connections and higher centrality of the miRNAs, TFs and target genes in the survival network studied suggest that network-based approaches to prognosticate or predict ovarian cancer survival may be more effective than those for ovarian cancer recurrence. This study demonstrated the feasibility to infer reliable miRNA-TF-target gene networks associated with survival and recurrence of ovarian cancer based on the simultaneous analysis of co-expression profiles and consideration of the clinical characteristics of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.